11 June 2024

Combination pharmacotherapy reduced methamphetamine intake in clinical trials

American researchers presented an analysis of the results of randomised controlled trials of adjunctive combination therapy for methamphetamine use disorder. A publication about it appeared in the journal Addiction. In it, Michael Li (Michael Li) from the University of California, Los Angeles, and his colleagues from the United States presented the secondary results of the second phase of the ADAPT-2 trial. In it, 403 people with methamphetamine addiction received the opioid receptor antagonist naltrexone (380 milligrams every three weeks by injection as an intramuscular capsule) and the antidepressant bupropion (450 milligrams per day orally as a slow-release tablet) or placebo for 12 weeks. Methamphetamine intake levels were measured by urine tests twice weekly during treatment and once at one and four weeks after the end of treatment.

Active medication increased the mean probability of a negative methamphetamine test by 27.1 per cent (95 per cent confidence interval 13.2-41.1 per cent; p < 0.001). When placebo was administered, the rate was 11.4 per cent (95 per cent confidence interval 4.1-18.6 per cent; p = 0.002). The mean probability of a negative test result in the main group was 15.8 per cent higher than in the control group (95 per cent confidence interval 4.5-27.0 per cent; p = 0.006).

Found a typo? Select it and press ctrl + enter Print version